The slope for all significant factors on the number of steps before a fall across all three speeds. by Amy Mitchell (3208905)

Subjects:

Adjusted surgical quality, adjusted cost, and market shares of innovative procedures, 2002–2015. by Ning Ning (464160)

Subjects:

Transportation plan when the amount of medical waste generated increases significantly. by Chen Hao (352436)

This is Transportation plan when the amount of medical waste generated increases significantly. by Chen Hao (352436)

Unadjusted and adjusted annualized growth rates of quality and cost for 11 surgery categories, 2002–2015. by Ning Ning (464160)

Subjects:

Unadjusted rates of high-quality stays and cost for 11 inpatient surgery categories, 2002–2015. by Ning Ning (464160)

Subjects:

Perioperative factors associated with differences in adjusted hospitalization costs; all displayed factors are significantly associated with increased or decreased adjusted costs. by Saad Mallick (17283479)

“…<p>Perioperative factors associated with differences in adjusted hospitalization costs; all displayed factors are significantly associated with increased or decreased adjusted costs.…”

Significant variables in decreasing importance for varietal clustering based on Random forest method. by Wilfried Chevalier (10521466)

Base-case value per patient, range, and description of costs in cost-effectiveness analyses for ACF with CXR and semi-PCF with CXR. by Sangwook Park (379863)

The 11 surgery categories and corresponding sample sizes, 2002–2015. by Ning Ning (464160)

Subjects:

Top shares of innovative ICD-9-CM procedures in 2015, compared with 2002. by Ning Ning (464160)

Subjects:

Pumping cost multiplier function represents increasing costs of pumping water with lowering groundwater level. by Kat Demaree (16274130)

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects: